{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:50:54Z","timestamp":1792083054366,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015696","name":"Siemens Healthineers USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhepr.2026.102018","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:48:14Z","timestamp":1788850094000},"page":"102018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis"],"prefix":"10.1016","author":[{"given":"Mazen","family":"Noureddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calum","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8947","authenticated-orcid":false,"given":"Manuel","family":"Romero-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-4381","authenticated-orcid":false,"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-8594","authenticated-orcid":false,"given":"Douglas T.","family":"Dieterich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5069-2461","authenticated-orcid":false,"given":"Emmanuel A.","family":"Tsochatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib2","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"MASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"The American Journal of Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102018_bib3","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/hep.28677","article-title":"Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort","volume":"64","author":"Setiawan","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of MASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Current Hepatology Reports"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib5","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102018_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis","volume":"41","author":"Schattenberg","year":"2021","journal-title":"Liver International"},{"issue":"3","key":"10.1016\/j.jhepr.2026.102018_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102018_bib9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lead individuals: expert review","volume":"163","author":"Long","year":"2022","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib12","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","article-title":"Past, present and future perspectives in nonalcoholic fatty liver disease","volume":"16","author":"Sanyal","year":"2019","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients With type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jhepr.2026.102018_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with MASLD: A systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib17","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/hep4.1411","article-title":"Impact of implementing a \"FIB-4 First\" strategy on a pathway for patients with MASLD referred from primary care","volume":"3","author":"Davyduke","year":"2019","journal-title":"Hepatology Communications"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib18","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1007\/s00330-015-3731-2","article-title":"Cost-utility analysis of nonalcoholic steatohepatitis screening","volume":"25","author":"Zhang","year":"2015","journal-title":"European Radiology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib21","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/j.gastro.2021.04.074","article-title":"Preparing for the MASH epidemic: a call to action","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2021.10.008","article-title":"Clinical Practice Guideline Panel, Chair, EGB representative, Panel members. Reply to: Correspondence on \"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update\"","volume":"76","year":"2022","journal-title":"J Hepatology"},{"issue":"10","key":"10.1016\/j.jhepr.2026.102018_bib23","first-page":"2656","article-title":"The Nimble stage 1 study validates diagnostic circulating biomarkers for nonalcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Research Square Preprint"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12876-020-01234-x","article-title":"Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy","volume":"201","author":"Liang","year":"2020","journal-title":"BMC Gastroenterology"},{"issue":"11","key":"10.1016\/j.jhepr.2026.102018_bib25","first-page":"913","article-title":"Association of the magnitude of weight loss and physical fitness change on long-term CVD outcomes: the Look AHEAD Study","volume":"4","year":"2017","journal-title":"Lancet Diabetes Endocrinology"},{"issue":"12","key":"10.1016\/j.jhepr.2026.102018_bib26","first-page":"1113","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"New England Journal of Medicine [e-journal]"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib27","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Digestive Diseases and Sciences"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102018_bib28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1478-3231.2011.02482.x","article-title":"Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors","volume":"31","author":"Leite","year":"2011","journal-title":"Liver International"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/art.1780380306","volume":"38","author":"Bergquist","year":"1995","journal-title":"Arthritis Rheumatology"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102018_bib31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocrine Practice"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib32","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102018_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102018_bib34","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.jhepr.2026.102018_bib35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","article-title":"Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia","volume":"71","author":"Serra-Burriel","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2026.102018_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2020.100142","article-title":"Cost of non-alcoholic steatohepatitis in Europe and the USA: the GAIN study","volume":"2","author":"O'Hara","year":"2020","journal-title":"JHEP Reports"},{"key":"10.1016\/j.jhepr.2026.102018_bib37","unstructured":"Bark.com. (2023). How Much Does It Cost To Hire A Dietician 2023 | Nutritionist Prices UK. Available at: https:\/\/www.bark.com\/en\/gb\/nutritionist\/nutritionist-price-guide\/ [Accessed 3 Jan. 2024]"},{"key":"10.1016\/j.jhepr.2026.102018_bib38","unstructured":"International Affiliate of the Academy of Nutrition and Dietetics. (2019). Available at: https:\/\/eatrightinternational.org\/wp-content\/uploads\/2019\/05\/germany-cis-2018-edited-2019.pdf (Accessed: 3 January 2024)"},{"key":"10.1016\/j.jhepr.2026.102018_bib39","unstructured":"RAMQ, B - Tarification des visites \/ Manuel de facturation des m\u00e9decins sp\u00e9cialistes. Available from: https:\/\/www.ramq.gouv.qc.ca\/SiteCollectionDocuments\/professionnels\/manuels\/150-facturation-specialistes\/012_b_tarif_visites_acte_spec.pdf. (Accessed: 2 June 2023)"},{"key":"10.1016\/j.jhepr.2026.102018_bib40","unstructured":"Italian Ministry of Health. Available from: http:\/\/www.salute.gov.it\/. (Accessed: 2 June 2023)"},{"issue":"6","key":"10.1016\/j.jhepr.2026.102018_bib41","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eimc.2011.11.004","article-title":"Evaluation of the costs of transient elastography (FibroScan\u00ae) in the diagnosis of liver fibrosis in HIV patients with hepatitis C virus","volume":"30","author":"Garc\u00eda-Jurado","year":"2012","journal-title":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"},{"key":"10.1016\/j.jhepr.2026.102018_bib42","unstructured":"CMS.gov 2020;Volume 2019. Available at: https:\/\/www.cms.gov\/apps\/ama\/license.asp?file\u00bc\/files\/zip\/20clabq2.zip. (Accessed: 2 June 2023)"},{"key":"10.1016\/j.jhepr.2026.102018_bib43","unstructured":"Madrigal Pharmaceuticals. Madrigal pharmaceuticals announces FDA approval of Rezdiffra\u2122 (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. 2024. https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm"},{"key":"10.1016\/j.jhepr.2026.102018_bib44","unstructured":"U.S. Food & Drug Administration. FDA approves treatment for serious liver disease known as 'MASH'. 2025. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:02:09Z","timestamp":1792080129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":44,"alternative-id":["S2589555926002892"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102018","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102018"}}